Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synergy Pharmaceuticals, Inc.

https://www.synergypharma.com/

Latest From Synergy Pharmaceuticals, Inc.

Ardelyx Gets IBS-C Approval, But Focus Remains On Hyperphosphatemia

Tenapanor approved for IBS-C as Ibsrela, but Ardelyx is still seeking a commercial partner for that indication – and is maintaining focus on same molecule in hyperphosphatemia.

Approvals Business Strategies

Keeping Track: US FDA Approvals For Ibsrela, Gvoke And Nucala; A BTD For Tepotinib

The latest drug development news and highlights from our US FDA Performance Tracker. 

US FDA Performance Tracker Approvals

Zelnorm Returning To US Market With Broad IBS-C Indication

US FDA limiting use of Zelnorm, originally pulled from the market in 2007 by its then-sponsor Novartis, to adult women who are at low CV risk, but tegaserod is not restricted to patients who are severely symptomatic for IBS-C. 

Approvals Gastrointestinal

Seventure Reaffirms Microbiome Confidence With New €200m Fund

With its first microbiome fund completing its investment period, French venture capitalist Seventure Partners has raised more than €100m of a €200m target for its second microbiome-focused fund.

Financing StartUps and SMEs
See All

Company Information

  • Other Names / Subsidiaries
    • Callisto Pharmaceuticals, Inc.
UsernamePublicRestriction

Register